Idiopathic Pulmonary Fibrosis

Pulmonary fibrosis is a chronic, progressive lung disorder characterized by scarring (fibrosis), thickening, hardening, and stiffening of the lung tissues. When the cause of the disease is unknown, it is termed “idiopathic.” Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial lung disease (ILD).

There is no permanent cure for IPF, but the treatment can focus on relieving symptoms, decreasing the progression, and improving the quality of life. The treatment plan includes certain oral medications, oxygen therapy, pulmonary rehabilitation, and lung transplant at a severe stage. Other than these, potential self-care preventive measures such as quitting smoking, eating healthy foods, being proactive, preventing yourself from infections, and breathing exercises should be included.

There are currently two medications approved for treating idiopathic pulmonary fibrosis. One of these medications is Bronchonib 150 mg capsule. It works by inhibiting certain abnormal proteins called tyrosine kinase. Bronchonib 150 mg capsule interferes with certain pathways that involve in the formation of lung fibrosis. The medicine is not recommended in patients with moderate or severe liver injury. For more visit Idiopathic Pulmonary Fibrosis